<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3841209/" ref="ordinalpos=3043&amp;ncbi_uid=5523343&amp;link_uid=PMC3841209" image-link="/pmc/articles/PMC3841209/figure/F9/" class="imagepopup">Figure. From: Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer. </a></div><br /><div class="p4l_captionBody"><b>Figure 9.</b> EGFR and BRAF/ERK signaling pathway.</div></div>